Skip to main content
Top
Published in: Inflammation 5/2019

01-10-2019 | Original Article

miR-140-5p Attenuates Neuroinflammation and Brain Injury in Rats Following Intracerebral Hemorrhage by Targeting TLR4

Authors: Shunda Wang, Yujie Cui, Jiaqi Xu, Heng Gao

Published in: Inflammation | Issue 5/2019

Login to get access

Abstract

The Toll-like receptor 4 (TLR4)–mediated neuroinflammation plays a key role in inducing secondary brain injury after intracerebral hemorrhage (ICH). However, how TLR4 is regulated during this pathological process is not well understood. In the present study, by taking advantage of a rat ICH model, we show that miR-140-5p is reversely correlated with TLR4 expression in the peri-hematomal striatum following ICH. In vitro, miR-140-5p directly targets TLR4 and suppresses its expression in a rat neuronal PC12 cell line. Moreover, an intracerebral ventricular injection of miR-140-5p mimics improves neurological function and reduces apoptotic cell death and limits the production of inflammatory cytokines following ICH, indicating that miR-140-5p attenuates brain injury and neuroinflammation in vivo. Furthermore, miR-140-5p suppresses TLR4 expression and inhibits the downstream MyD88/TRIF inflammatory pathway and NF-κB activity following ICH, suggesting that the inhibition of TLR4-mediated neuroinflammation at least in part accounts for the neuroprotective role of miR-140-5 against ICH-induced brain injury in rats. Collectively, these results identify miR-140-5 as a negative regulator of TLR4 and downstream inflammatory pathway following ICH, implicating that miR-140-5 might represent as a potential therapeutic target for alleviating ICH-induced brain injury.
Literature
13.
go back to reference Lewis, B.P., I.H. Shih, M.W. Jones-Rhoades, D.P. Bartel, and C.B. Burge. 2003. Prediction of mammalian microRNA targets. Cell 115 (7): 787–798.CrossRefPubMed Lewis, B.P., I.H. Shih, M.W. Jones-Rhoades, D.P. Bartel, and C.B. Burge. 2003. Prediction of mammalian microRNA targets. Cell 115 (7): 787–798.CrossRefPubMed
21.
23.
go back to reference Johnson, J.D., W.G. Conroy, and G.E. Isom. 1987. Alteration of cytosolic calcium levels in PC12 cells by potassium cyanide. Toxicology and Applied Pharmacology 88 (2): 217–224.CrossRefPubMed Johnson, J.D., W.G. Conroy, and G.E. Isom. 1987. Alteration of cytosolic calcium levels in PC12 cells by potassium cyanide. Toxicology and Applied Pharmacology 88 (2): 217–224.CrossRefPubMed
28.
go back to reference Sun, D.G., B.C. Xin, D. Wu, L. Zhou, H.B. Wu, W. Gong, and J. Lv. 2017. miR-140-5p-mediated regulation of the proliferation and differentiation of human dental pulp stem cells occurs through the lipopolysaccharide/toll-like receptor 4 signaling pathway. European Journal of Oral Sciences 125 (6): 419–425. https://doi.org/10.1111/eos.12384.CrossRefPubMed Sun, D.G., B.C. Xin, D. Wu, L. Zhou, H.B. Wu, W. Gong, and J. Lv. 2017. miR-140-5p-mediated regulation of the proliferation and differentiation of human dental pulp stem cells occurs through the lipopolysaccharide/toll-like receptor 4 signaling pathway. European Journal of Oral Sciences 125 (6): 419–425. https://​doi.​org/​10.​1111/​eos.​12384.CrossRefPubMed
Metadata
Title
miR-140-5p Attenuates Neuroinflammation and Brain Injury in Rats Following Intracerebral Hemorrhage by Targeting TLR4
Authors
Shunda Wang
Yujie Cui
Jiaqi Xu
Heng Gao
Publication date
01-10-2019
Publisher
Springer US
Published in
Inflammation / Issue 5/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-01049-3

Other articles of this Issue 5/2019

Inflammation 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine